-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA accepts Takeda psoriasis drug zasocitinib NDA for priority review

PUBT·09/14/2026 07:00:51
Listen to the news
FDA accepts Takeda psoriasis drug zasocitinib NDA for priority review
  • FDA accepted Takeda’s NDA for psoriasis drug candidate zasocitinib under Priority Review.
  • PDUFA target action date set for Q1 2027.
  • Filing backed by Phase 3 data showing about 70% achieved clear or almost clear skin at week 16.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609140300BIZWIRE_USPR_____20260914_BW748441) on September 14, 2026, and is solely responsible for the information contained therein.